OncoRiftCANCER RESEARCH. TRACEABLE EVIDENCE.Open workspace ↗
A CLEARER LENS ON CANCER RESEARCH

Every insight starts
with evidence.

Extraordinary responses deserve a closer look. OncoRift is building a way to connect scattered cancer research to the original evidence—and the people who can make sense of it.

+A shared foundation. Disease-specific research.
22 concept tracks · GBM and PDAC remain core priorities
OBSERVATIONSOURCEINTERPRETATIONCONTEXT
CONNECT THE EVIDENCE.
PRESERVE THE CONTEXT.
FIG. 01 / THE EVIDENCE NETWORK
Built for scientific scrutinyExact source passages ↗Versioned interpretations ↗Human review at the core ↗
01 / THE APPROACH

Follow the evidence.
Keep the nuance.

Research is more than a collection of conclusions. It’s the wording of an observation, the timing of a treatment, the uncertainty in a diagnosis.

OncoRift is designed to keep those details visible. Original observations stay separate from interpretations, so every proposed connection can be inspected, challenged, and revisited.

01 Original observations02 Versioned interpretations03 Pinned knowledge
RESEARCH TRACKS / SCOPE BEFORE SCALE

More cancers.
The same evidence standard.

22 concept tracks cover the 20 leading global cancer mortality categories, plus a dedicated GBM track and melanoma. GBM and PDAC remain our initial pilot priorities.

Selection basis

Global number of cancer deaths, both sexes, all ages. IARC · GLOBOCAN 2024, version 1.0 ↗ · Accessed October 19, 2026.

Mortality categories are broader than some research scopes. PDAC is a pancreatic subset; GBM sits within brain/CNS. This is not a ranking of individual prognosis.

All tracks are concepts. Only GBM and PDAC currently have illustrative source-passage examples. Other tracks provide proposed scope, extraction fields, and review requirements; no live corpus or evaluated extraction is claimed.

02 / THE RESEARCH WORKSPACE

A question.
A trail you can follow.

Explore how a researcher could move from a paper to a source-linked observation—and into independent review.

INTERACTIVE CONCEPT · SYNTHETIC DATA
Research workspace / Evidence explorerR
PANCREATIC DUCTAL ADENOCARCINOMA

Evidence explorer

Find the observation. Inspect the context. Keep the uncertainty.

Concept previewEvery record and passage below is fictional. They demonstrate the workflow, not clinical findings.
3 illustrative recordsTrack-specific · Source-linked
03 / INTEGRITY BY DESIGN

Uncertainty is part
of the evidence.

A useful research tool should make it easier to see what a source supports—and where it stops.

01

Reported isn’t inferred.

A protein assay is preserved as an assay. A proposed genetic interpretation stays a separate, reviewable claim.

02

Missing isn’t negative.

Not reported, not tested, indeterminate, and explicitly negative findings need different meanings.

03

Timing changes the question.

Induction and maintenance treatments stay distinct. Survival and objective response stay distinct, too.

04 / WHERE WE ARE

Building the foundation.
Then earning the insight.

This site shows the product direction.
The research software is an experimental prototype.

IMPLEMENTED FOUNDATION

Evidence tooling

Metadata indexing, source validation, PDAC cohort safeguards, citation checking, and annotation tools.

89 software tests passed in the audited snapshot. Live integrations still need verification.
NEXT MILESTONE

A 10 + 10 paper pilot

Start with a reproducible GBM and PDAC pilot, then establish disease-specific protocols for additional tracks. Verify citations, source versions, and article-level rights.

No completed real-paper pilot or adjudicated reference corpus yet.
REQUIRES RESEARCH PARTNERS

Independent evaluation

Two qualified reviewers, preserved annotation drafts, adjudication, and separate measurements for each disease track.

No scientific extraction benchmark scores have been established.
THE PURPOSE BEHIND THE PLATFORM

Less time chasing sources.
More time asking better questions.

Built to help researchers inspect, challenge, and reproduce evidence.

Explore the concept ↗